お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
923903

ヒト免疫不全ウイルス (HIV) :アンメットニーズを対象にする画期的医薬品 (ファーストインクラス)

HIV: First-in-Class Therapies Target Major Unmet Needs Including Drug Resistance and Latency Reversal

出版日: | 発行: GlobalData | ページ情報: 英文 63 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円
ヒト免疫不全ウイルス (HIV) :アンメットニーズを対象にする画期的医薬品 (ファーストインクラス)
出版日: 2019年12月31日
発行: GlobalData
ページ情報: 英文 63 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ヒト免疫不全ウイルス(HIV)は、性的接触、妊娠、母乳育児、注射器具の共有、輸血などの手段によって、血液、精液、その他の体液から感染する可能性がある慢性疾患です。

当レポートでは、世界のヒト免疫不全ウイルス(HIV)治療薬市場について調査分析し、疾患の概要とガイドライン、パイプライン製品の評価、主要企業などについて、体系的な情報を提供しています。

第1章 目次

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 疾患の概要

  • 病因と病態生理
  • 分類または病期
  • HIVの持続的イノベーション
  • HIVの疫学
  • 上市製品の概要

第5章 パイプライン製品イノベーションの評価

  • 概要
  • パイプライン:開発段階・分子タイプ別
  • パイプライン:分子標的別
  • HIV市場とパイプライン間のプログラムの比較分布:治療標的ファミリー別
  • ファーストインクラスと非ファーストインクラスのパイプラインプログラムの比較分布:分子標的クラス別
  • ファーストインクラスと非ファーストインクラスのパイプラインプログラムの比較分布
  • パイプライン内のファーストインクラス分子標的に対するファーストインクラスプログラムの比率

第6章 ファーストインクラスの分子標的の評価

  • 概要
  • インターロイキン2受容体サブユニットベータIL2RBとインターロイキン2受容体サブユニットガンマを標的とするパイプラインプログラム
  • Toll様受容体3を標的とするパイプラインプログラム
  • プロテインキナーゼCイプシロンタイプとプロテインキナーゼCシータタイプを標的とするパイプラインプログラム
  • CD209抗原を標的とするパイプラインプログラム
  • サイクリン依存性キナーゼ9を標的とするパイプラインプログラム
  • IgG低親和性III受容体のFcフラグメントを標的とするパイプラインプログラム
  • 2',5'-オリゴアデニル酸シンテターゼ1を標的とするパイプラインプログラム
  • セリン/アルギニンリッチスプライシング因子10を標的とするパイプラインプログラム

第7章 主要企業と取引

  • 概要

第8章 付録

図表

List of Tables

  • Table 1: WHO Clinical Staging of HIV/AIDS for Adults and Adolescents with Confirmed HIV Infection, 2016
  • Table 2: HIV Total Prevalent Cases (N), 2015-2025

List of Figures

  • Figure 1: HIV, Global Market by Molecular Target and Molecule Type, 2019
  • Figure 2: HIV, Global, Pipeline by Stage of Development and Molecule Type, 2019
  • Figure 3: HIV, Global, Pipeline by Molecular Target and Stage of Development, 2019
  • Figure 4: HIV Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2019
  • Figure 5: HIV, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2019
  • Figure 6: HIV, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2019
  • Figure 7: HIV, Global, Ratio of First-in-Class and Non-First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019
目次
Product Code: GDHC499FP

Human immunodeficiency virus (HIV) is a chronic disease that can be transmitted through blood, semen, and other bodily fluids by means such as sexual contact, pregnancy and breastfeeding, the sharing of injection drug equipment, and blood transfusions.

As the disease progresses, the virus causes depletion of a type of immune cell known as cluster of differentiation 4 (CD4) cells in the infected host. The loss of these cells leads to the progressive deterioration of the immune system, eventually resulting in the development of acquired immunodeficiency syndrome (AIDS), which is associated with multiple opportunistic infections.

Without treatment, HIV can progress to AIDS and may be fatal within a number of years. However, when appropriately managed with antiretroviral therapy (ART), HIV patients can achieve a near-normal life-expectancy.

Despite this, there is a continuing need to develop innovative new therapies for HIV, particularly among highly treated patients in whom HIV has developed resistance to one or more drugs.

Scope

  • The HIV pipeline is large, with more than 400 programs in active development. What proportion of these products are first-in-class? How does first-in-class innovation vary by development stage and molecular target class?
  • Approximately 50 first-in-class targets have been identified within the HIV pipeline. Among these, what is the distribution of host versus viral targets? Which of the host targets are considered to be most promising?
  • Across the HIV landscape, there are more than 250 active companies. Which companies have formed partnerships? Which companies have first-in-class assets in development with no prior deal involvement?

Reasons to buy

  • Understand the current disease landscape with an in-depth discussion of etiology, pathophysiology, disease classification and staging systems, epidemiology, and marketed therapies for HIV.
  • Analyze the HIV pipeline, and stratify pipeline assets by stage of development, molecule type, and molecular target.
  • Assess the therapeutic potential of first-in-class molecular targets. Using a proprietary matrix assessment, host first-in-class molecular targets for HIV have been assessed and ranked according to clinical potential, and the most promising of these targets are reviewed in greater detail. Key features of viral first-in-class targets are also outlined.
  • Analyze company strategies in prior deals through case studies of key deals for HIV first-in-class products, and recognize commercial opportunities by identifying first-in-class pipeline products that have not yet been involved in licensing or co-development deals.

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 HIV: Executive Summary

  • 2.1 Current Market Landscape Needs Further Novel Therapies
  • 2.2 High Level of Pipeline Innovation Aims to Address Drug Resistance and Pill Burden
  • 2.3 First-in-Class Therapies Target Latent HIV Reservoirs and Drug Resistance, with Potential for Prevention and Even Cure of HIV

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification or Staging Systems
  • 4.3 Sustained Innovation in HIV
  • 4.4 Epidemiology for HIV
  • 4.5 Overview for Marketed Products

5 Assessment of Pipeline Product Innovation

  • 5.1 Overview
  • 5.2 Pipeline by Stage of Development and Molecule Type
  • 5.3 Pipeline by Molecular Target
  • 5.4 Comparative Distribution of Programs Between HIV Market and Pipeline by Therapeutic Target Family
  • 5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
    • 5.5.1 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs
  • 5.6 Ratio of First-in-Class Programs to First-in-Class Molecular Target Within the Pipeline

6 First-in-Class Molecular Target Evaluation

  • 6.1 Overview
  • 6.2 Pipeline Programs Targeting Interleukin 2 Receptor Subunit Beta IL2RB and Interleukin 2 Receptor Subunit Gamma
  • 6.3 Pipeline Programs Targeting Toll-Like Receptor 3
  • 6.4 Pipeline Programs Targeting Protein Kinase C Epsilon Type and Protein Kinase C Theta Type
  • 6.5 Pipeline Programs Targeting CD209 Antigen
  • 6.6 Pipeline Programs Targeting Cyclin-Dependent Kinase 9
  • 6.7 Pipeline Programs Targeting Fc Fragment of IgG Low-Affinity III Receptor
  • 6.8 Pipeline Programs Targeting 2'-5'-Oligoadenylate Synthetase 1
  • 6.9 Pipeline Programs Targeting Serine/Arginine Rich Splicing Factor 10

7 Key Players and Deals

  • 7.1 Overview
    • 7.1.1 Gilead Sciences Entered a Co-development Deal with Aelix Therapeutics
    • 7.1.2 GeoVax Labs Entered into a Co-development Deal with American Gene Technologies
    • 7.1.3 BryoLogyx Entered into a Licensing Agreement with Stanford University

8 Appendix

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.